http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011226926-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_acc770deb80d458f8846e248423f9092 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2011-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4610d0640d0058859389fc14b13f83ae |
| publicationDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2011226926-A1 |
| titleOfInvention | Alzheimer's disease treatment method |
| abstract | Alzheimer's Disease Treatment Method The invention relates to antibodies which are used in the preparation of a 5 medicament for the treatment of Alzheimer's disease. More specifically, yhe invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease. |
| priorityDate | 2003-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.